Get the Stockscreener App
5.47
0.18%
0.010
Curevac N V stock is traded at $5.47, with a volume of 458.13K.
It is up +0.18% in the last 24 hours and up +0.37% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.46
Open:
$5.47
24h Volume:
458.13K
Relative Volume:
0.38
Market Cap:
$1.23B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.9745
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
+1.11%
1M Performance:
+0.37%
6M Performance:
+45.09%
1Y Performance:
+72.56%
1-Day Range:
$5.45
$5.495
1-Week Range:
$5.35
$5.495
52-Week Range:
$2.37
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.47 | 1.23B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
Will CureVac N.V. stock benefit from AI tech trendsFast Gaining Stock Screener Reports Released - metal.it
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update - The Manila Times
Is CureVac N.V. a good long term investmentFree Investment Portfolio Suggestions - Jammu Links News
Bullish Candlestick Pattern Forms in CureVac N.V.AI Based High Gain Watchlist Scanner Shared - beatles.ru
What is CureVac N.V. company’s growth strategyMassive wealth growth - Jammu Links News
Should I hold or sell CureVac N.V. stock in 2025Superior portfolio returns - Jammu Links News
What makes CureVac N.V. stock price move sharplyHigh-return market picks - Jammu Links News
When is CureVac N.V. stock expected to show significant growthGet expert advice on portfolio optimization - Jammu Links News
CureVac N.V. Stock Analysis and ForecastMaximize gains with data-driven stock picks - Jammu Links News
How volatile is CureVac N.V. stock compared to the marketStay ahead with daily market updates - Jammu Links News
Does CureVac N.V. stock perform well during market downturnsGet daily expert analysis for smarter investing - Jammu Links News
What are analysts’ price targets for CureVac N.V. in the next 12 monthsUnlock daily stock market insights for success - Jammu Links News
Is it the right time to buy CureVac N.V. stockSignificant capital appreciation - Jammu Links News
How strong is CureVac N.V. company’s balance sheetRetirement Planning Signals To Watch Now - jammulinksnews.com
Is CureVac N.V. stock overvalued or undervaluedReal Time Signals For Consistent Profits - Jammu Links News
Why CureVac N.V. stock attracts strong analyst attentionPattern Detection for Entry Confirmation Enabled - beatles.ru
Short Covering May Lift CureVac N.V. in Near TermRisk Adjusted Technical Entry Plan Gains Followers - metal.it
CureVac N.V.Finanzen.net - Finanzen.net
Traders Consider Averaging Down in CureVac N.V.Smart Investment Tips Gaining Popularity Among Analysts - metal.it
How does CureVac N.V. generate profit in a changing economyTremendous wealth creation - Jammu Links News
Why is CureVac N.V. stock attracting strong analyst attentionMaximize returns with expert trading insights - Jammu Links News
What is the dividend policy of CureVac N.V. stockBuild a balanced portfolio for long-term success - Jammu Links News
What drives CureVac N.V. stock priceExplosive trading opportunities - PrintWeekIndia
Will CureVac N.V. stock benefit from interest rate changesFree Stock Market Real-Time Monitoring - Jammu Links News
DekaBank Deutsche Girozentrale Buys Shares of 1,941 CureVac (NASDAQ:CVAC) - 富途牛牛
What analysts say about CureVac N.V. stockExponential return rates - Autocar Professional
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):